Compare NRG Energy Inc (NRG) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs Novartis AG — how do they compare? NRG Energy Inc trades at $107.45 (market cap $22.35B), while Novartis AG trades at $143.35 (market cap $268.57B). The key difference: Novartis AG is far larger — about 12× NRG Energy Inc's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold NRG Energy Inc for 62 Days and Novartis AG for 82 Days on average.
| NRG | NVS | |
|---|---|---|
Market Cap | $22.35B | $268.57B |
Volume | 5,011,942 | 1,532,573 |
Sector | Utilities | Health |
52-Week High | $184.03 | $168.62 |
52-Week Low | $95.23 | $121.80 |
Typical Hold Time | 62 Days | 82 Days |
Enterprise Value | $46.30B | $309.89B |
Dividend Yield | 1.79% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy (NRG) trades at $108.61, up 4.84% today, with a bullish technical signal and strong analyst consensus. Recent earnings showed a Q2 2026 miss but the company is executing a growth strategy including a 1.2 GW Texas data-center power project. Financials indicate solid revenue of $30.71B in 2025, though net margins are thin at 2.56%, and cash flow trends are volatile with a projected net outflow in 2026.
The outlook is positive given high analyst buy ratings and a $202.90 price target, but risks include execution on large capital projects, rising debt levels, and competitive pressures. Earnings growth from new assets and customer relationships remains the key catalyst for upside, though the stock faces near-term volatility from recent misses.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
